IDO1 and ovarian carcinoma: Wang et al. found that indoleamine 2,3-dioxygenase 1 (IDO1) enhances chemoresistance of ovarian cancer cells through inhibition of cisplatin-induced ROS accumulation and activation of p53 signaling pathway [17].